Regeneron Pharmaceuticals, Inc. $REGN Position Increased by New York Life Investment Management LLC

New York Life Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 15,087 shares of the biopharmaceutical company’s stock after buying an additional 1,144 shares during the quarter. New York Life Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $11,645,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. WPG Advisers LLC raised its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares in the last quarter. Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Torren Management LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $38,000. FNY Investment Advisers LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $38,000. Finally, Oakworth Capital Inc. increased its position in Regeneron Pharmaceuticals by 124.0% during the fourth quarter. Oakworth Capital Inc. now owns 56 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 31 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Down 2.1%

Shares of NASDAQ:REGN opened at $698.25 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a market cap of $73.82 billion, a P/E ratio of 17.01, a P/E/G ratio of 1.58 and a beta of 0.30. The stock’s 50-day moving average is $744.69 and its 200-day moving average is $744.97. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period last year, the business earned $8.22 earnings per share. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.1 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several analyst reports. Evercore increased their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $825.00 to $800.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 30th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. Finally, Piper Sandler initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 31st. They set an “overweight” rating and a $875.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $826.59.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.